Interview: Indian family-owned firms becoming more open to sell-off option
This article was originally published in Scrip
Selling off the family jewels, or even a discussion on the issue, was considered unthinkable in closely-held, family-owned Indian pharmaceutical firms even just a few years ago.
You may also be interested in...
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.